|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||36.62 - 37.04|
|52 Week Range||31.67 - 39.43|
|PE Ratio (TTM)||10.46|
|Forward Dividend & Yield||1.36 (3.72%)|
|1y Target Est||N/A|
Alan Valdes, director of floor operations at Silverbear Capital, joins Yahoo Finance's Seana Smith from the floor of the New York Stock Exchange to discuss the latest market moves.
Pfizer's CEO Ian Read could make almost $28 million in the next year to keep him from retiring. Strangely enough, he may earn it given the healthcare and political environment.
AstraZeneca, Bristol and Vertex are the likeliest targets of widespread mergers and acquisitions across the biopharma group.
As discussed earlier, Pfizer’s (PFE) revenue rose ~1% to $13.7 billion during 4Q17 driven by increased sales of its Innovative Health products. It reflects revenues for both Pfizer’s Innovative Health and Essential Health segments in 4Q17. Pfizer reported a fall of ~4% in its US sales in 4Q17, while its sales outside US markets reported a 5% revenue rise in the quarter.
In 4Q17, Merck’s (MRK) Invanz generated revenues of $157 million, which represents a ~3% rise on a YoY (year-over-year) basis and a 1% decline on a QoQ (quarter-over-quarter). In 4Q17, in the US and in international markets, Invanz generated revenues of $93 million and $64 million, respectively, compared with $90 million and $63 million in 4Q16, which represents a ~4% rise and a ~2% rise, respectively, YoY. In 2017, Invanz reported revenues of $602 million, compared with $561 million in 2016, which is ~7% higher YoY.
Pfizer Inc. boosted Chief Executive Officer Ian Read’s compensation for 2017 to $27.9 million, a 61 percent increase, to ensure he stays on the job.
This week I discuss two dividend paying companies that both beat top and bottom line expectations and are expected to greatly benefit from the new tax reform law over the next few years. These companies are Pfizer Inc. (PFE), and Delta Air lines Inc. (DAL).
In 4Q17, Merck’s (MRK) Cubicin reported revenues of $92 million, which was ~23% lower on a YoY (year-over-year) basis but 1% higher on a QoQ (quarter-over-quarter) basis. In 4Q17, in the US and in international markets, Cubicin generated revenues of $40 million and $52 million, respectively, compared with $82 million and $36 million in 4Q16, which reflected a ~51% decline and 43% rise, respectively, YoY. In fiscal 2017, Cubicin reported revenues of $382 million, compared with $1.1 billion in 2016.
The Retirement Systems of Alabama manages assets that totaled $38.4 billion at Sept. 30, 2016, for state pensions and trusts. RSA also owns a number of prominent real-estate properties, including Manhattan skyscraper 55 Water Street and the Robert Trent Jones Golf Trail, a collection of courses. The manager’s largest investment however is in domestic stocks, and as of Dec. 31 it had $20.7 billion invested in U.S.-traded securities.
The biotech sector was in focus last week with key news - Orexigen going bankrupt, Biogen acquires asset from Pfizer, Regeneron cuts Praluent price among others.
Biogen has agreed to acquire a schizophrenia drug candidate from New York-based pharmaceutical giant Pfizer Inc. The purchase allows Cambridge, Massachusetts-based Biogen (BIIB) to develop a new treatment for cognitive impairment. “When cognition is impaired, you lose the ability to make sense of the world," said Michael Ehlers, executive vice president, Research & Development at Biogen.
Biogen (BIIB) agrees to pay $75 million upfront to buy mid-stage candidate from Pfizer, which is being developed for cognitive impairment associated with schizophrenia (CIAS).